Document is current
Any future updates will be listed below
-
Authors
Choi, Huiyeon
Yamauchi, Takuji https://orcid.org/0000-0002-6238-3145
Mori, Yasuo
Matsuo, Chie
Nishihara, Hakuei
Irifune, Hidetoshi
Nakao, Fumihiko
Ishihara, Daisuke
Imanaga, Hiroshi
Sasaki, Kensuke
Sakoda, Teppei
Jinnouchi, Fumiaki
Miyawaki, Kohta
Shima, Takahiro
Kikushige, Yoshikane
Akashi, Koichi
Kato, Koji
- License Information
-
More Information
Article History
Received: 22 June 2025
Revised: 21 October 2025
Accepted: 22 October 2025
First Online: 31 October 2025
Declarations
:
: This study was supported in part by a Grant-in-Aid for Scientific Research (C) to T. Yamauchi (No. 20796213), from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This study was also supported in part by research grants from Shin-nihon Foundation of Advanced Medical Treatment Research, Chugai Foundation for Innovative Drug Discovery Science, and Japanese Society of Hematology (to T. Yamauchi).
: This study was approved by the Institutional Review Board of Kyushu University Hospital. All patients provided written informed consent prior to treatment, in accordance with the Declaration of Helsinki (1975, as revised in 1983). As the use of nivolumab in combination with cytotoxic chemotherapy is not approved under the national insurance system in Japan, the treatment was conducted under IRB oversight. No animal studies were involved. Study registration was not applicable.
